( Pooled Findings Presented at 2007 APA M...)Pooled Studies Showed Desvenlafaxine Succinate Significantly,Improved Painful Symptoms and Anxious Symptoms Associated with,Major Depressive Disorder in Adults, Compared With Placebo,Health

COLLEGEVILLE, Pa., May 21, 2007 /PRNewswire-FirstCall/ -- Findings from two separate pooled analyses - one examining the effect of desvenlafaxine succinate on anxious symptoms and the other on painful symptoms associated with major depressive disorder (MDD) -- as well as a separate pooled analysis that examined the effect of desvenlafaxine succinate on weight change in patients with MDD were presented today at the 2007 American Psychiatric Association (APA) annual meeting in San Diego, Calif., by Wyeth Pharmaceuticals, a division of Wyeth . The primary objective of studies included in these pooled analyses was to evaluate efficacy and safety of desvenlafaxine succinate in adults with MDD.

"People don't always connect painful physical symptoms and anxious symptoms with depression, but these can be very real symptoms of the illness," says Philip Ninan, M.D., Vice President, Neuroscience, Global Medical Affairs for Wyeth Pharmaceuticals. "In addition, weight gain is a relatively common concern of patients who are treated with antidepressants. We are encouraged by the results of these pooled analyses which show that desvenlafaxine, if approved, may be an important option for the treatment of adult patients with major depressive disorder."

The most common adverse event associated with desvenlafaxine succinate in the pooled analyses was transient nausea.

About the Studies

Poster NR366: Tourian K, et al. Improvement of Anxiety Symptoms in Patients with Major Depressive Disorder Treated with Desvenlafaxine Succinate: A Pooled Analysis

Results of a pooled analysis of seven studies showed that adult patients who took desvenlafaxine succinate experienced a greater improvement in mild and moderate symptoms of anxiety associated with depression compared with those who rece
'"/>